AARD

Aardvark Therapeutics, Inc.

5.32 USD

Last updated Sep 4, 19:42 UTC

Yesterday HIGH

$6.19

Yesterday LOW

$5.6

52w HIGH

$17.94

52w LOW

$3.35

EPS

-0.66

PE

-8.06

Next Earnings

Nov 12, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Aardvark Therapeutics, Inc. stock is down -29.26% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 September’s closed higher than August. In the last 4 Unusual Options Trades, there were 4 CALLs.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

13 Jul 16:38	21 Aug, 2026	7.50	CALL	495	2883
14 Jul 16:18	21 Aug, 2026	7.50	CALL	200	3466
14 Jul 18:05	21 Aug, 2026	7.50	CALL	200	3466
16 Jul 18:00	21 Aug, 2026	7.50	CALL	365	3866

Advanced Data Unlock

Benzinga Newsdesk

Fri May 15, 2026

BTIG Downgrades Aardvark Therapeutics to Neutral

BTIG analyst Jeet Mukherjee downgrades Aardvark Therapeutics (NASDAQ:AARD) from Buy to Neutral.
Vandana Singh

Fri May 15, 2026

FDA Halts Aardvark Therapeutics Rare Disease Study

FDA places full clinical hold on Aardvark's ARD-101 studies as the company reviews Phase 3 safety and efficacy data.
Avi Kapoor

Fri May 15, 2026

This BWX Technologies Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

Top Wall Street analysts upgraded RXO, BWXT, and Timken stocks with higher price targets. See other analysts' views on these stocks.
Avi Kapoor

Fri May 15, 2026

This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.
Benzinga Insights

Fri May 15, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Newsdesk

Fri May 15, 2026

Morgan Stanley Downgrades Aardvark Therapeutics to Underweight, Lowers Price Target to $3

Morgan Stanley analyst Michael Ulz downgrades Aardvark Therapeutics (NASDAQ:AARD) from Equal-Weight to Underweight and lowers the price target from $7 to $3.
Avi Kapoor

Fri May 15, 2026

Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Figma Inc (NYSE: FIG) shares rose 10.6% in pre-market trading after beating Q1 revenue and earnings estimates and raising FY26 sales guidance.
Benzinga Insights

Thu May 14, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Newsdesk

Thu May 14, 2026

Aardvark Therapeutics Says FDA Places Full Clinical Hold On Its Investigational New Drug Application For ARD-101 Related To Prior Announced Voluntary Pause

Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Benzinga Newsdesk

Thu May 7, 2026

Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate

Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.90) by 10 percent. This is a 39.44 percent decrease over losses of $(0.71) per share